Shares of Cempra, Inc. (NASDAQ:CEMP) added 8.96% by the end of trading session at $3.65. For the current quarter, the 13 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$0.59/share, which would compare with -$0.48 in the year-ago quarter. The net percentage change is -83.31% over the last 12 months. The trading range in the same period had a highest hit of $26.95 while lowest level was $2.55. At the moment the price is -52.33% below its 50-day moving average and -78.25% below its 200-day moving average.
Cempra, Inc. (NASDAQ:CEMP) on January 4, 2017 announced that it will be participating in the 35th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present at 3:30 p.m. PT (6:30 p.m. ET) on Wednesday, January 11, 2017 in San Francisco. Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP).
Heat Biologics, Inc. (NASDAQ:HTBX) last exchanged hands at a price $1.06/share, registering a gain of 8.1%. Among 1 Wall Street analysts tracked by Thomson/First Call, the average PT for HTBX is $4 but some of them are predicting the price to move at the $4 level. If the most optimistic analysts are correct, the expected total return from the current price would be 277.36. The number of shares traded in most recent trading day was 2.66M shares which averages 2.7M shares a day. Its previous fifty two week high was $3.35 and moved down -57.11% over the same time frame, currently having a market cap around $23.39 million. Shares have risen -10.22% over the trailing six months. At the moment, the stock trades -17.26% below its 50-day moving average and 2.11% above its 200-day moving average.
Heat Biologics, Inc. (NASDAQ:HTBX) on January 5, 2017 announced that Jeff Wolf, Heat’s Chief Executive Officer, will present an overview of the company at the Biotech Showcase 2017 Conference on Wednesday, January 11, 2017, at 9:30 a.m. Pacific Standard Time in Room 3, at the Hilton San Francisco Union Square in San Francisco, California. Heat Biologics, Inc. (HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, form the basis of its product candidates.